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Background. Current guidelines recommend a susceptibility-based regimen for Mycobacterium abscessus subspecies abscessus 
pulmonary disease (MAB-PD), but the evidence is weak. We aimed to investigate the association between treatment outcomes and 
in vitro drug susceptibility to injectable antibiotics in MAB-PD patients.
Methods. We enrolled MAB-PD patients treated with intravenous amikacin and beta-lactams for ≥4 weeks at 4 referral hos-
pitals in Seoul, South Korea. Culture conversion and microbiological cure at 1 year were evaluated based on susceptibility to inject-
able antibiotics among patients treated with those antibiotics for ≥2 weeks.
Results. A total of 82 patients were analyzed. The mean age was 58.7 years, and 65.9% were women. Sputum culture conver-
sion and microbiological cure were achieved in 52.4% and 41.5% of patients, respectively. Amikacin was the most common agent 
to which the M. abscessus subspecies abscessus isolates were susceptible (81.7%); 9.8% and 24.0% of the isolates were resistant to 
cefoxitin and imipenem, respectively. The clarithromycin-inducible resistance (IR) group (n = 65) had a lower microbiological cure 
rate than the clarithromycin-susceptible group (35.4% vs 64.7%). The treatment outcomes appeared to be similar regardless of in 
vitro susceptibility results with regard to intravenous amikacin, cefoxitin, imipenem, and moxifloxacin. In the subgroup analysis of 
the clarithromycin-IR group, the treatment outcomes did not differ according to antibiotic susceptibility.
Conclusions. We did not find evidence supporting the use of susceptibility-based treatment with intravenous amikacin and 
beta-lactams in patients with MAB-PD. Further research is required.
Keywords.  amikacin; beta-lactams; microbial sensitivity tests; Mycobacterium abscessus; nontuberculous mycobacteria; treat-
ment outcome.
The incidence of nontuberculous mycobacterial pulmonary 
disease has increased worldwide in recent decades [1, 2]. The 
Mycobacterium abscessus complex is one of the most important 
causative organisms of nontuberculous mycobacterial pulmo-
nary disease and comprises 3 distinct subspecies: M. abscessus 
subspecies abscessus, M.  abscessus subspecies bolletii, and 
M. abscessus subspecies massiliense [3].
Treatment for M. abscessus subspecies abscessus pulmonary 
disease (MAB-PD) is challenging because of the frequency of 
intrinsic resistance to common antibiotics. According to a re-
cent meta-analysis, the treatment success rate in patients with 
MAB-PD was only 30%–40% [4, 5]. Macrolide resistance due 
to either mutational or inducible resistance (IR) related to the 
presence of a functional erm(41) gene in M. abscessus subspe-
cies abscessus is associated with worse treatment outcomes in 
patients with MAB-PD [3, 6].
For the treatment of MAB-PD, recent guidelines have suggested 
a multidrug regimen, including at least 3 or 4 active drugs guided 
by in vitro drug susceptibility results [7, 8]. Especially in the initial 
phase, the administration of 2 or 3 intravenous antibiotics for at 
least 1 month is recommended [7, 8]. However, the drug suscep-
tibility test (DST) of M. abscessus subspecies abscessus is difficult 
and controversial. Macrolides are the only oral agents that show a 
correlation between in vitro susceptibility and treatment response 
in patients with MAB-PD. For other antimicrobial agents, there is 
no established correlation between susceptibility and the clinical 
response [9, 10]. Therefore, we aimed to investigate the impact of 
in vitro testing of susceptibility to intravenous antibiotics on treat-
ment outcomes in patients with MAB-PD.
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METHODS
Study Design and Population
This was a multicenter retrospective cohort study. We inte-
grated the medical records of patients with MAB-PD from 
the 4 tertiary referral centers in Seoul, South Korea (Asan 
Medical Centre [AMC], Samsung Medical Centre [SMC], 
Seoul National University Hospital [SNUH], and Severance 
Hospital). The study population met the American Thoracic 
Society/Infectious Diseases Society of America (ATS/IDSA) di-
agnostic criteria [11].
Previously published data from the 2 referral centers were 
obtained first: Clinical data of patients diagnosed between 
January 2002 and December 2012 were obtained from a pro-
spective, observational cohort at the SMC [12], and the data of 
patients diagnosed between January 2006 and June 2015 were 
obtained from a retrospective cohort study at the SNUH [13]. 
Additional cohort data from the other 2 referral centers were 
retrospectively reviewed: Data of patients diagnosed between 
March 2012 and December 2018 at Severance Hospital were 
collected, and data of patients diagnosed between July 2012 and 
December 2019 at AMC were collected.
Patients with MAB-PD treated with intravenous amikacin 
and beta-lactams for ≥4 weeks were included. We excluded 
the following patients: those with clarithromycin-resistant 
M.  abscessus subspecies abscessus isolates, those treated with 
amikacin nebulizers, those who had no DST results for intra-
venous antibiotics, and those with insufficient data. According 
to the previously defined categories, radiographic abnormalities 
were measured based on chest computed tomography at initial 
diagnosis [12]. A positive result on the acid-fast bacilli (AFB) 
smear or the presence of cavitary lung lesions was considered to 
indicate extensive disease.
The primary outcome measures were culture conversion 
and microbiological cure according to susceptibility to inject-
able antibiotics in patients with MAB-PD. Secondary outcome 
measures were treatment outcomes according to antibiotic sus-
ceptibility in subgroups based on disease severity, macrolide 
susceptibility, and treatment duration.
Microbiological Examination
According to the standard guidelines, we performed AFB 
smears and mycobacterial cultures of respiratory specimens [7, 
14]. Sputum or bronchoscopy samples were cultured in solid 
medium (Ogawa medium; Korean Institute of Tuberculosis, 
Cheongju, South Korea) and liquid medium (BACTEC 960 
Mycobacterial Growth Indicator Tube; Becton Dickinson, 
Sparks, MD, USA). The species of NTM isolates were identified 
by polymerase chain reaction and restriction fragment length 
polymorphism methods based on the rpoB gene or sequencing 
of the rpoB and tuf genes [15, 16]. Species differentiation be-
tween M.  abscessus subspecies abscessus and M.  massiliense 
subspecies massiliense was performed based on the erm(41) 
gene detected by polymerase chain reaction [17] or multilocus 
sequencing analysis of the rrs, hsp65, and rpoB genes [18].
Three centers (SMC, SNUH, and Severance) sent samples 
to the Korean Institute of Tuberculosis, a supranational refer-
ence laboratory, for antibiotic susceptibility testing. AMC sent 
samples to the same laboratory between December 1, 2015, and 
January 4, 2019; otherwise, the in-house laboratory performed 
the DSTs using the Sensititre RAPMYCO or RAPMYCOI plate 
(Thermo Fisher Scientific, Waltham, MA, USA). The broth 
microdilution method was used for all tests, and the cutoff 
points for antibiotic susceptibility were those set by the Clinical 
and Laboratory Standards Institute guidelines [19, 20].
The first reported minimal inhibitory concentration (MIC) 
for M.  abscessus subspecies abscessus strains was used in this 
study. The MIC of clarithromycin was measured on days 3 and 14 
after incubation. M. abscessus subspecies abscessus isolates were 
regarded as macrolide susceptible if the clarithromycin MIC 
was ≤2 μg/mL on days 3 and 14 or as macrolide resistant if the 
clarithromycin MIC was ≥8 μg/mL on day 3. If the isolates were 
susceptible on day 3 but resistant on day 14 of incubation, we 
considered them clarithromycin-IR. Genetic analysis was con-
ducted for M. abscessus subspecies abscessus strains of the SMC, 
and those with the presence of the C28 sequevar in the erm(41) 
gene were regarded as clarithromycin susceptible [12, 21]. We 
conducted subgroup analyses with the clarithromycin-IR group 
because macrolide susceptibility affects treatment outcomes 
[21–23]. Follow-up DST results were compared with the initial 
test result when available.
Treatment Modalities and Outcomes
Treatment modalities varied among the centers. All patients at 
SMC were hospitalized and received treatment with a 4-week 
fixed course of amikacin and cefoxitin with oral macrolide, 
fluoroquinolone, and doxycycline [12]. After discharge, pa-
tients maintained an oral regimen for at least 12 months after 
sputum culture conversion. In the other 3 centers, the treatment 
duration of intravenous antibiotics was determined by the at-
tending physician. Combination therapy with oral macrolide 
and at least 2 intravenous amikacin and beta-lactam antibiotics 
was prescribed for 3 or 4 weeks during the initial hospitaliza-
tion. After discharge, a macrolide-based regimen with optional 
outpatient-based intravenous amikacin 3–5 times a week was 
maintained. The total duration of intravenous antibiotic admin-
istration was decided by the attending physicians at each center 
based on the occurrence of clinico-radiological improvement or 
drug-related adverse events.
We used the NTM-NET consensus statement to define 
the treatment outcomes in this study [24]. Culture conver-
sion was defined as 3 consecutive negative cultures from 
respiratory samples during treatment. Microbiological cure 
was defined as the absence of positive cultures of NTM 
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after achieving culture conversion and maintaining that for 
1  year after treatment initiation. In addition, radiographic 
responses were evaluated at 1 year after treatment. We ana-
lyzed patients who received the antibiotics of interest for ≥2 
weeks to investigate the association between antibiotic sus-
ceptibility and treatment outcomes.
Statistical Analysis
Continuous variables were compared using the Student t test 
or the Mann-Whitney U test; categorical variables were ana-
lyzed using the Pearson χ 2 test or Fisher exact test. All statis-
tical analyses were performed with R software, version 4.0.2 
(The R Foundation for Statistical Computing, Vienna, Austria). 
A 2-tailed P value <.05 was considered statistically significant 
for all analyses.
Patient Consent Statement
The institutional review board of each center, including 
Severance Hospital (4-2020-0952), approved the study protocol. 
The need for patient consent was waived because the study was 
based on a retrospective analysis and previously published data.
RESULTS
Baseline Characteristics and Overall Treatment Outcomes
A total of 127 patients (AMC, 39; SMC, 67; SNUH, 9; Severance, 
12) were initially enrolled from the 4 referral centers; eligibility 
screening identified 82 patients (AMC, 37; SMC, 35; SNUH, 
6; Severance, 4) (Figure 1). The mean age was 58.7 years, and 
65.9% were women (Table 1). There were 65 participants with 
MAB-PD who were infected with clarithromycin-IR strains.
Table 2 shows the treatment regimens and outcomes in 
the study population. The median treatment duration was 
15.4 months, and the treatment durations and modalities were 
similar between the clarithromycin-IR and clarithromycin-
susceptible groups. All participants were treated with intra-
venous amikacin and beta-lactams for ≥4 weeks combined 
with an oral macrolide. Among them, approximately one-
third of participants took oral clofazimine or moxifloxacin. 
Radiologic improvements were observed in 42.7% of patients, 
and sputum culture conversion and microbiological cure were 
achieved in 52.4% and 41.5%, respectively. The presence of 
clarithromycin-IR was related to a lower microbiological cure 
rate with marginal statistical significance (35.4% vs 64.7%; 
P = .056).
Antibiotic Susceptibility and Treatment Outcomes
Supplementary Table 1 presents the antibiotic susceptibility pro-
file of the entire population. Amikacin was the most common 
agent to which the isolates were susceptible (81.7%), followed 
by linezolid (60.7%). In total, 9.8% and 24.0% of the isolates 
were resistant to cefoxitin and imipenem, respectively.
Figure 2 and Table 3 show the antibiotic susceptibility and 
treatment outcomes in patients treated with the agents of in-
terest for at least 2 weeks. The overall sputum culture conver-
sion rate and microbiological cure rate were similar regardless 
of the susceptibility to injectable antibiotics.
We performed subgroup analyses based on disease severity, 
treatment duration, and clarithromycin susceptibility. In pa-
tients with cavitary lesions and patients with positive smears 
and cavitary lesions, antibiotic susceptibility to amikacin 
seemed to be related to the treatment outcomes, but this finding 
should be interpreted with caution as the number of isolates 
in the resistant group was small (Supplementary Table 2). 
Among patients treated for ≥1  year, the microbiological cure 
rate was related to the cefoxitin susceptibility pattern (P = .025) 
(Supplementary Table 3). The microbiological cure rate was also 
different based on cefoxitin susceptibility in patients with posi-
tive smear results (P = .021).
When we analyzed 65 patients with clarithromycin-IR 
strains, treatment outcomes were similar regardless of whether 
the strains were susceptible to amikacin, cefoxitin, imipenem, 
or moxifloxacin (Table 4). In patients with cavitary lesions, 
amikacin susceptibility seemed to be related to the treatment 
outcomes, but the amikacin-resistant group was small.
There were 43 patients with a median follow-up DST 
of 19.6  months. We compared the results of amikacin sus-
ceptibility from the 2 DSTs to assess resistance emergence 
(Supplementary Table 4). There were 13 patients with an 
increased MIC and 15 patients with a decreased MIC for 
amikacin; the culture conversion rates were similar be-
tween the 2 groups (P = .699). Among the 34 patients 
with amikacin-susceptible isolates on the initial test, 4 
showed intermediate susceptibility and 2 showed resist-
ance to amikacin on the follow-up test. The intermediate 
and resistant groups on the initial test also showed a similar 
127 patients with Mycobacterium abscessus PO
treated with IV amikacin and IV beta-lactam
for ≥4 weeks
82 patients eligible for analysis
Excluded (n = 45)
Insucient data (n = 37)
MIC of  CLR ≥8 (n = 6)





Figure 1. Study population. Abbreviations: CLR, clarithromycin; CLR-IR, 
clarithromycin inducible resistance; CLR-S, clarithromycin susceptible; MIC, min-
imal inhibitory concentration; PD, pulmonary disease.
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pattern on the follow-up test. The culture conversion rates 
according to the initial and follow-up DST results were sim-
ilar (Supplementary Table 5).
Adverse Drug Events
Adverse drug events related to intravenous antibiotics are pre-
sented in Table 5. Among 82 participants, 41 patients (50%) 
Table 2. Treatment Regimen and Outcomes
Total (n = 82) CLR-S (n = 17) CLR-IR (n = 65) P Value
Treatment duration, mo 15.4 (9.5–24.5) 14.7 (7.5–24.1) 15.7 (10.6–24.8) .430
IV amikacin duration, wk 8.9 (4.0–27.1) 14.7 (4.0–27.1) 7.3 (4.0–27.1) .638
IV beta-lactam duration, wk 5.3 (4.0–9.4) 5.4 (4.0–10.4) 5.1 (4.0–9.4) >.999
IV beta-lactam, type 82 (100.0) 17 (100.0) 65 (100.0) .109
 Cefoxitin 33 (40.2) 9 (52.9) 24 (36.9)  
 Cefoxitin to imipenem 37 (45.1) 6 (35.3) 31 (47.7)  
 Imipenem 11 (13.4) 1 (5.9) 10 (15.4)  
 Imipenem to cefoxitin 1 (1.2) 1 (5.9) 0 (0.0)  
Macrolide 82 (100.0) 17 (100.0) 65 (100.0) .336
 AZT 50 (61.0) 10 (58.8) 40 (61.5)  
 AZT to CLR 11 (13.4) 4 (23.5) 7 (10.8)  
 CLR 21 (25.6) 3 (17.6) 18 (27.7)  
 CLR to AZT 0 (0.0) 0 (0.0) 0 (0.0)  
Other drugs
 Clofazimine 23 (28.0) 2 (11.8) 21 (32.3) .169
 Moxifloxacin 26 (31.7) 5 (29.4) 21 (32.3) >.999
 Linezolid 4 (4.9) 0 (0.0) 4 (6.2) .677
Surgical resection within 1 y 6 (7.3) 0 (0.0) 6 (9.2) .436
Radiographic response
 Improved 35 (42.7) 8 (47.1) 27 (41.5) .776
 Unchanged 31(37.8) 7 (7.0) 24 (36.9)  
 Worsened 16 (19.5) 2 (11.8) 14 (21.5)  
Culture conversion 43 (52.4) 12 (70.6) 31 (47.7) .158
Microbiological cure 34 (41.5) 11 (64.7) 23 (35.4) .056
Data are presented as No. (%) or median (interquartile range).
Abbreviations: AZT, azithromycin; CLR, clarithromycin; CLR-IR, clarithromycin inducible resistant; CLR-S, clarithromycin susceptible.
Table 1. Baseline Characteristics
Total (n = 82) CLR-S (n = 17) CLR-IR (n = 65) P Value
Age, y 58.7 ± 11.4 60.5 ± 13.8 58.2 ± 10.8 .452
Sex, female 54 (65.9) 12 (70.6) 42 (64.6) .861
BMI, kg/m2 20.4 ± 2.8 21.3 ± 1.6 20.2 ± 3.0 .038
BMI <18.5 kg/m2 22 (26.8) 1 (5.9) 21 (32.3) .060
Smoking, current or past 18 (22.0) 4 (23.5) 14 (21.5) >.999
History of tuberculosis 39 (47.6) 6 (35.3) 33 (50.8) .387
History of NTM treatment 9 (11.0) 1 (5.9) 8 (12.3) .750
Comorbidities
 Bronchiectasis 73 (89.0) 16 (94.1) 57 (87.7) .750
 COPD 5 (6.1) 3 (17.6) 2 (3.1) .096
 Diabetes mellitus 9 (11.0) 1 (5.9) 8 (12.3) .750
 Chronic kidney disease 2 (2.4) 2 (11.8) 0 (0.0) .055
Radiological type    .446
 Fibrocavitary 14 (17.1) 1 (5.9) 13 (20.0)  
 Cavitary NB 20 (24.4) 6 (35.3) 14 (21.5)  
 Noncavitary NB 44 (53.7) 9 (52.9) 35 (53.8)  
 Unclassifiable 4 (4.9) 1 (5.9) 3 (4.6)  
Smear, positive 65 (79.3) 13 (76.5) 52 (80.0) >.999
Presence of cavity 35 (42.7) 7 (41.2) 28 (43.1) >.999
Follow-up after treatment, median (IQR), mo 13.7 (3.0–36.0) 8.4 (3.3–34.1) 15.9 (2.8–41.9) .499
Data are presented as No. (%) or mean ± SD, unless otherwise indicated.
Abbreviations: BMI, body mass index; CLR-IR, clarithromycin inducible resistant; CLR-S, clarithromycin susceptible; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; 
NB, nodular bronchiectatic; NTM, nontuberculous mycobacteria.
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experienced an adverse event related to intravenous antibiotics. 
Four patients (4.9%) experienced ototoxicity due to amikacin, 
and 19 patients (27.1%) developed hematologic abnormalities, 
such as leukopenia, due to cefoxitin. Hematologic abnormal-
ities were the most frequent adverse reactions to imipenem 
usage (10.2%).
DISCUSSION
Current guidelines suggest susceptibility-based treatment 
rather than empirical therapy for patients with MAB-PD [7, 
8]. However, it is currently unknown whether a susceptibility-
based regimen results in better treatment outcomes. To the best 
of our knowledge, this is the first study investigating this aspect 
of the treatment of MAB-PD; the evidence supporting the use 
of susceptibility-based treatment is inconclusive with regard to 
injectable antibiotics.
MAB-PD is often considered an incurable chronic disease 
because M. abscessus subspecies abscessus is highly virulent and 
chemo-resistant [25]. Several research groups have investigated 
the association between macrolide susceptibility and treat-
ment outcomes in patients with MAB-PD. It is well known that 
macrolide-based therapy is useful for cases of infection with 
macrolide-susceptible strains [21–23]. Previous reports stated 
that ~20% of M.  abscessus subspecies abscessus isolates were 
macrolide susceptible due to a C28 sequevar of the erm(41) 
gene [26–28]. In the present study, 20.7% of the patients were 
infected with clarithromycin-susceptible isolates, and those 
patients had more favorable outcomes than the patients with 
clarithromycin-IR isolates.
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Figure 2. Antibiotic susceptibility profile and treatment outcomes in patients treated with the intravenous antibiotics of interest for ≥2 weeks. The upper panel shows the 
minimal inhibitory concentration of (A) amikacin, (B) cefoxitin, and (C) imipenem. The middle panel shows the sputum culture conversion rate according to the minimal inhib-
itory concentration of (D) amikacin, (E) cefoxitin, and (F) imipenem. The lower panel shows the microbiological cure rate according to the minimal inhibitory concentration of 
(G) amikacin, (H) cefoxitin, and (I) imipenem. Abbreviations: I, intermediate; R, resistant; S, susceptible.
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However, most patients were infected with 
clarithromycin-IR strains in this study, as in previous re-
ports [27, 28]. Although macrolides could be used for their 
immunomodulatory properties or antimicrobial effects 
against co-infecting organisms, they are not considered ac-
tive antibiotics against macrolide-IR or macrolide-resistant 
strains [7]. Therefore, the use of at least 4 drugs other than 
macrolides is recommended in the initial phase, including in-
travenous amikacin, imipenem (or cefoxitin), and tigecycline 
[7].
Most isolates of M.  abscessus subspecies abscessus are sus-
ceptible or intermediately susceptible to amikacin [27, 28]. 
Although intravenous amikacin was administered for a median 
of 8.9 weeks in this study and although every patient main-
tained treatment with amikacin for at least 4 weeks in the initial 
phase, the overall treatment success rate was unsatisfactory ir-
respective of the amikacin susceptibility results (Tables 3 and 4). 
This implies that the impact of in vitro amikacin susceptibility 
on treatment outcomes is limited. For clinicians, great concerns 
regarding the long-term use of amikacin include the occurrence 
of adverse drug events and the emergence of resistant strains. 
Similar to a previous report [29], ototoxicity and nephrotoxicity 
were the main adverse events in the present study.
Data on the emergence of resistance to amikacin during 
treatment are scarce. In the CONVERT study of refractory 
M. avium complex pulmonary disease, 23 (10.3%) of 224 pa-
tients in the inhaled liposomal amikacin group had isolates with 
a postbaseline amikacin MIC >64 mcg/mL, but 21.7% of these 
subsequently had isolates with an MIC <64 mcg/mL [30]. In 
addition, there is the issue of frequent reinfection in NTM-PD 
[31, 32]. Thus, we did not determine the effect of amikacin use 
on the emergence of resistant strains in our study.
Kwak et al. found that treatment with imipenem was asso-
ciated with better results in patients with MAB-PD [4]. In our 
study, the overall microbiological cure rate was 43.5% in pa-
tients treated with cefoxitin and 27.6% in those treated with 
imipenem (P = .230, calculated from Table 3). Adverse reac-
tions seemed to be frequent in patients treated with cefoxitin. 
In a large-scale study in Korea, 24% and 13% of clinically iso-
lated M.  abscessus subspecies abscessus strains had in vitro 
resistance to imipenem and cefoxitin, respectively [28]. The 
results in our study were similar: Cefoxitin resistance was iden-
tified in 9.8%, and imipenem resistance was identified in 24.0%. 
However, beta-lactam susceptibility was not related to the treat-
ment success rate in this study, except for the microbiological 
cure rate in those treated for ≥1  year (Supplementary Table 
3). It is noteworthy that 7 out of 82 patients (8.5%) had strains 
that were resistant to both imipenem and cefoxitin, 2 of whom 
achieved a microbiological cure with cefoxitin and imipenem. 
Therefore, we should not merely rely on susceptibility results to 
guide the selection of beta-lactams but should consider diverse 
aspects, such as the patient’s other medical conditions or ad-
verse drug events.
We do not suggest that there is no need to consider antibi-
otic susceptibility when selecting the treatment regimen for 
MAB-PD. In contrast, we strongly suggest further research on 
Table 3. Antibiotic Susceptibility Profile and Treatment Outcomes in Patients Treated With the Antibiotics of Interest for ≥2 Weeks
Susceptible Intermediate Resistant P Valuea P Valueb
Amikacin (n = 82) 67 (81.7) 12 (14.6) 3 (3.7)   
 Culture conversion 33 (49.3) 8 (66.7) 2 (66.7) .513 >.999
 Microbiological cure 25 (37.3) 8 (66.7) 1 (33.3) .170 >.999
Cefoxitin (n = 62) 18 (29.0) 36 (58.1) 8 (12.9)   
 Culture conversion 12 (66.7) 20 (55.6) 3 (37.5) .384 .279
 Microbiological cure 11 (61.1) 15 (41.7) 2 (25.0) .223 .276
Ciprofloxacin (n = 17)   17 (100.0)   
 Culture conversion   11 (64.7) NA NA
 Microbiological cure   10 (58.8) NA NA
Clarithromycin (n = 82) 17 (20.7)  65 (79.3)c   
 Culture conversion 12 (70.6)  31 (47.7) NA .159
 Microbiological cure 11 (64.7)  23 (35.4) NA .056
Imipenem (n = 29) 12 (41.4) 12 (41.4) 5 (17.2)   
 Culture conversion 4 (33.3) 5 (41.7) 3 (60.0) .703 .622
 Microbiological cure 3 (25.0) 3 (25.0) 2 (40.0) .746 .597
Moxifloxacin (n = 26) 1 (3.8) 2 (7.7) 23 (88.5)   
 Culture conversion 1 (100.0) 0 (0.0) 9 (39.1) .292 >.999
 Microbiological cure 1 (100.0) 0 (0.0) 7 (30.4) .372 >.999
Data are presented as No. (%). We omitted antibiotic subgroups with <10 patients taking those antibiotics for ≥2 weeks.
Abbreviation: NA, not available.
aP value among the susceptible, intermediate, and resistant groups.
bP value between the susceptible plus intermediate group and the resistant group.
cInducible resistance.
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this issue for the following reasons. First, large-scale multina-
tional data are needed to determine the clinical implications 
of DST and enable generalization of the results. Although we 
enrolled patients with MAB-PD from the 4 largest referral 
centers in Korea, the number of cases was insufficient. Only 3 
patients were infected with amikacin-resistant strains, which 
Table 4. Antibiotic Susceptibility Profile and Treatment Outcomes in 65 Patients With CLR-IR M. abscessus Subspecies abscessus Strains
Susceptible Intermediate Resistant P Valuea P Valueb
CLR-IR
Amikacin (n = 65) 52 (80.0) 11 (16.9) 2 (3.1)   
 Culture conversion 23 (44.2) 7 (63.6) 1 (50.0) .503 >.999
 Microbiological cure 15 (28.8) 7 (63.6) 1 (50.0) .082 >.999
Cefoxitin (n = 47) 13 (27.7) 27 (57.4) 7 (14.9)   
 Culture conversion 8 (61.5) 14 (51.9) 2 (28.6) .369 .379
 Microbiological cure 7 (53.8) 9 (33.3) 2 (28.6) .388 .692
Imipenem (n = 26) 10 (38.5) 12 (46.2) 4 (15.4)   
 Culture conversion 3 (30.0) 5 (41.7) 2 (50.0) .748 >.999
 Microbiological cure 2 (20.0) 3 (25.0) 2 (50.0) .509 .604
Moxifloxacin (n = 21)  2 (9.5) 19 (90.5)   
 Culture conversion  0 (0.0) 7 (36.8) NA .793
 Microbiological cure  0 (0.0) 6 (31.6) NA .906
CLR-IR & positive smear
Amikacin (n = 52) 43 (82.7) 8 (15.4) 1 (1.9)   
 Culture conversion 17 (39.5) 5 (62.5) 0 (0.0) .332 >.999
 Microbiological cure 10 (23.3) 5 (62.5) 0 (0.0) .065 >.999
Cefoxitin (n = 37) 9 (24.3) 23 (62.2) 5 (13.5)   
 Culture conversion 5 (55.6) 11 (47.8) 1 (20.0) .423 .442
 Microbiological cure 5 (55.6) 6 (26.1) 1 (20.0) .226 .901
Imipenem (n = 20) 6 (30.0) 11 (55.0) 3 (15.0)   
 Culture conversion 1 (16.7) 4 (36.4) 1 (33.3) .692 >.999
 Microbiological cure 1 (16.7) 2 (18.2) 1 (33.3) .820 >.999
Moxifloxacin (n = 18)  2 (11.1) 16 (88.9)   
 Culture conversion  0 (0.0) 5 (31.2) NA .926
 Microbiological cure  0 (0.0) 4 (25.0) NA >.999
CLR-IR & cavitary lesions
Amikacin (n = 28) 22 (78.6) 5 (17.9) 1 (3.6)   
 Culture conversion 9 (40.9) 5 (100.0) 0 (0.0) .035 >.999
 Microbiological cure 7 (31.8) 5 (100.0) 0 (0.0) .014 >.999
Cefoxitin (n = 23) 7 (30.4) 13 (56.5) 3 (13.0)   
 Culture conversion 3 (42.9) 8 (61.5) 1 (33.3) .569 .936
 Microbiological cure 3 (42.9) 7 (53.8) 1 (33.3) .775 >.999
Moxifloxacin (n = 10)  1 (10.0) 9 (90.0)   
 Culture conversion  0 (0.0) 3 (33.3) NA >.999
 Microbiological cure  0 (0.0) 3 (33.3) NA >.999
CLR-IR & treatment ≥1 y
Amikacin (n = 44) 32 (72.7) 10 (22.7) 2 (4.5)   
 Culture conversion 17 (53.1) 6 (60.0) 1 (50.0) .922 >.999
 Microbiological cure 11 (34.4) 6 (60.0) 1 (50.0) .343 >.999
Cefoxitin (n = 32) 8 (25.0) 17 (53.1) 7 (21.9)   
 Culture conversion 6 (75.0) 11 (64.7) 2 (28.6) .152 .149
 Microbiological cure 6 (75.0) 7 (41.2) 2 (28.6) .157 .503
Imipenem (n = 15) 5 (33.3) 7 (46.7) 3 (20.0)   
 Culture conversion 2 (40.0) 3 (42.9) 2 (66.7) .736 .897
 Microbiological cure 2 (40.0) 1 (14.3) 2 (66.7) .254 .494
Moxifloxacin (n = 16)  1 (6.2) 15 (93.8)   
 Culture conversion  0 (0.0) 6 (40.0) NA >.999
 Microbiological cure  0 (0.0) 5 (33.3) NA >.999
Data are presented as No. (%). We omitted antibiotic subgroups with <10 patients taking those antibiotics for ≥2 weeks.
Abbreviations: CLR-IR, clarithromycin inducible resistance; NA, not available.
aP value among the susceptible, intermediate, and resistant groups.
bP value between the susceptible plus intermediate group and the resistant group, unless otherwise indicated.
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Table 5. Adverse Drug Events Related to Intravenous Antibiotics
Total (n = 82) Amikacin (n = 82) Cefoxitin (n = 71) Imipenem (n = 49)
Any adverse events 41 (50.0) 9 (11.0) 27 (38.0) 7 (14.3)
Dermatologic abnormalities 4 (4.9) 0 (0.0) 4 (5.6) 1 (2.0)
Fever 6 (7.3) 1 (1.2) 5 (7.0) 0 (0.0)
Gastrointestinal abnormalities 2 (2.4) 0 (0.0) 1 (1.4) 1 (2.0)
Haematologic abnormalities 21 (25.6) 0 (0.0) 19 (27.1) 5 (10.2)
Hepatotoxicity 8 (9.8) 0 (0.0) 8 (11.2) 0 (0.0)
Nephrotoxicity 3 (3.7) 3 (3.7) 0 (0.0) 0 (0.0)
Ototoxicity 4 (4.9) 4 (4.9) 0 (0.0) 0 (0.0)
Peripheral neuropathy 1 (1.2) 1 (1.2) 0 (0.0) 0 (0.0)
Data are presented as No. (%).
limited the statistical power. Second, the stability of the anti-
biotics used in the DST should be considered with care because 
it has been reported that imipenem instability affects MIC re-
sults [33, 34]. Third, the relationship between susceptibility to 
other antimycobacterial drugs and the treatment success rate 
needs to be evaluated. In this study, linezolid seemed to be the 
second most effective drug against M.  abscessus subspecies 
abscessus after amikacin, but a very small number of patients 
were treated with it. Frequent adverse events associated with 
linezolid might be a barrier to its prescription [35]. Additionally, 
inhaled amikacin was also excluded from this analysis; there-
fore, we could not evaluate the additive effects of inhaled 
antibiotics. Fourth, it would be helpful to conduct additional 
studies with expanded susceptibility tests for other antibiotics. 
Tigecycline has been recommended as an initial choice in re-
cent guidelines [7, 8]. A lower MIC of clofazimine was associ-
ated with negative sputum culture conversion [36]. However, 
tigecycline and clofazimine susceptibility are not routinely 
tested at the Korean Institute of Tuberculosis, a supranational 
reference laboratory. Therefore, a wide range of DSTs should be 
performed in future studies. Fifth, treatment outcomes other 
than the rate of sputum culture conversion or microbiological 
cure need to be measured. As MAB-PD is considered an incur-
able disease, symptomatic improvements could be a new target. 
A susceptibility-based regimen might slow disease progression 
or improve quality of life. Finally, a standardized treatment mo-
dality is needed to measure treatment outcomes.
In conclusion, we did not find evidence supporting the use 
of susceptibility-based treatment with injectable amikacin 
and beta-lactams for MAB-PD patients. Further research is 
needed to clarify this issue and help physicians choose effective 
antimycobacterial agents for this chronic incurable disease.
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